Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to an unprecedented public health, economic, and social crisis worldwide. Since no therapeutic treatment is yet available to effectively clear the virus and terminate transmission, supportive therapy is the primary clinical approach for coronavirus disease (COVID-19). The role of corticosteroids as one of the main means of anti-inflammatory adjuvants in the treatment of COVID-19 is controversial. Here, we retrospectively evaluated the therapeutic effects of corticosteroids by comparing clinical data of patients treated with or without a corticosteroids therapy at different severity levels. Kaplan-Meier curves shows that therapy with methylprednisolone and cortico-steroids increases the risk of death in patients with critical COVID-19 pneumonia. For patients in the critical group, the risk of death was slightly higher in males receiving corticosteroids therapy, while hypertension and trauma history reduced the hazard ratio.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Naja, M., Wedderburn, L., Ciurtin, C.: COVID-19 infection in children and adolescents. Br. J. Hosp. Med. 81(8), 1–10 (2020)
Rhee, E.J., Kim, J.H., Moon, S.J., et al.: Encountering COVID-19 as endocrinologists. Endocrinol. Metab. 35(2), 197–205 (2020)
Fadel, R., Morrison, A.R., Vahia, A., et al.: Early short-course corticosteroids in hospitalized patients with COVID-19. Clin. Infect. Dis. 71(16), 2114–2120 (2020)
Miao, Y., Fan, L., Li, J.Y.: Potential treatments for COVID-19 related cytokine storm-beyond corticosteroids. Front. Immunol. 11, 1445 (2020)
Solinas, C., Perra, L., Aiello, M., et al.: A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine Growth Factor Rev. 54, 8–23 (2020)
Tlayjeh, H., Mhish, O.H., Enani, M.A., et al.: Association of corticosteroids use and outcomes in COVID-19 patients: a systematic review and meta-analysis. J. Infect. Public Health 13(11), 1652–1663 (2020)
Johnson, K.M., Belfer, J.J., Peterson, G.R., et al.: Managing COVID‐19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid‐sparing immunosuppression. Pharmacother. J. Human Pharmacol. Drug Therapy, 40(6), 517–524 (2020)
Arabi, Y.M., Chrousos, G.P., Meduri, G.U.: The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Intensive Care Med. 46(11), 2067–2070 (2020)
Mattos-Silva, P., Felix, N.S., Silva, P.L., et al.: Pros and cons of corticosteroid therapy for COVID-19 patients. Respir. Physiol. Neurobiol. 280, 103492 (2020)
Zhang, J., Xie, B., Hashimoto, K.: Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav. Immun. 87, 59–73 (2020)
Rizk, J.G., Kalantar-Zadeh, K., Mehra, M.R., et al.: Pharmaco-immunomodulatory therapy in COVID-19. Drugs 80(13), 1267–1292 (2020)
Sanders, J.M., Monogue, M.L., Jodlowski, T.Z., et al.: Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323(18), 1824–1836 (2020)
Matthay, M.A., Wick, K.D.: Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. J. Clin. Investig. 130(12), 6218–6221 (2020)
Shang, L., Zhao, J., Hu, Y., et al.: On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395(10225), 683–684 (2020)
Nicolau, D.V., Bafadhel, M.: Inhaled corticosteroids in virus pandemics: a treatment for COVID-19? Lancet Respir. Med. 8(9), 846 (2020)
Singh, A., et al.: Role of corticosteroid in the management of COVID-19: a systemic review and a Clinician’ perspective. Diab. Metab. Syndr. Clin. Res. Rev. 14(5), 971–978 ((2020))
Yang, J.W., Yang, L., Luo, R.G., et al.: Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin. Microbiol. Infect. 26(9), 1171–1177 (2020)
Hasan, S.S., Capstick, T., Ahmed, R., et al.: Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev. Respir. Med. 14(11), 1149–1163 (2020)
Wu, J., Huang, J., Zhu, G., et al.: Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China. J. Clin. Endocrinol. Metab. 105(12), e4230–e4239 (2020)
Liu, Z., Li, X., Fan, G., et al.: Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin. Microbiol. Infect. 27(1), 112–117 (2021)
Bartoletti, M., Marconi, L., Scudeller, L., et al.: Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin. Microbiol. Infect. 27(1), 105–111 (2021)
De Backer, D., Azoulay, E., Vincent, J.L.: Corticosteroids in severe COVID-19: a critical view of the evidence. Crit. Care 24(1), 1–3 (2020)
Herman, P., Vincent, C., Winkler, C.P., et al.: Consensus statement. corticosteroid therapy in ENT in the context of the COVID-19 pandemic. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 137(4), 315–317 (2020)
Alijotas-Reig, J., Esteve-Valverde, E., Belizna, C., et al.: Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun. Rev. 19(7), 102569 (2020)
Han, Y., Jiang, M., Xia, D., et al.: COVID-19 in a patient with long-term use of glucocorticoids: a study of a familial cluster. Clin. Immunol. 214, 108413 (2020)
Pasin, L., Navalesi, P., Zangrillo, A., et al.: Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. J. Cardiothorac. Vasc. Anesth. 35(2), 578–584 (2021)
Alexaki, V.I., Henneicke, H.: The Role of Glucocorticoids in the Management of COVID-19. Horm. Metab. Res. 53(01), 9–15 (2021)
Gustine, J.N., Jones, D.: Immunopathology of Hyperinflammation in COVID-19. Am. J. Pathol. 191(1), 4–17 (2021)
van Paassen, J., Vos, J.S., Hoekstra, E.M., et al.: Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit. Care 24(1), 1–22 (2020)
Kow, C.S., Hasan, S.S.: Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis. Infection 48(5), 805–806 (2020)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this paper
Cite this paper
Gao, Y., Sun, Y., Bi, J., Wang, S., Zhang, J., Xiao, M. (2022). Therapeutic Effects of Corticosteroids for Critical and Severe COVID-19 Patients. In: Tan, Y., Shi, Y. (eds) Data Mining and Big Data. DMBD 2022. Communications in Computer and Information Science, vol 1745. Springer, Singapore. https://doi.org/10.1007/978-981-19-8991-9_19
Download citation
DOI: https://doi.org/10.1007/978-981-19-8991-9_19
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-8990-2
Online ISBN: 978-981-19-8991-9
eBook Packages: Computer ScienceComputer Science (R0)